Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

ESH-EBMT-EHA 3rd Translational Research Conference

ESH-EBMT-EHA 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Read more

Tutorial on acute leukemia held in Istanbul

EHA and the Turkish Society of Hematology (TSH) partnered for the seventh time to organize a tutorial.

Read more

Is CBTH for me?

CBTH provides the development of computational biology skills for scholars who want to build successful careers in hematology research.

Read more

SWG Educational Activities

Past EHA (HOPE) Asia 2021 meeting 10-11 September 2021, Virutal

Speakers
Laane - Systematic review of literature on multiple myeloma EHA evidence-based “Guidelines for the use of patient-reported outcomes in adult patients with hematological malignancies” in progress - Systematic review of literature…

Read more

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more